Showing 6161-6170 of 7509 results for "".
- Cutera Rolls Out Heroes Among Us Programhttps://practicaldermatology.com/news/cutera-rolls-out-heroes-among-us-program/2460228/Cutera is launching its new “Heroes Among Us” program to showcase patients who’ve been positively affected by Cutera technologies. The new program was launched at the Cutera University Clinical Forum (CUCF) in Scott
- NavaDerm Partners Adds Dan Wechsler as Executive Chairmanhttps://practicaldermatology.com/news/navaderm-partners-adds-dan-wechsler-as-executive-chairman/2460225/Dan Wechsler is the new Executive Chairman of NavaDerm Partners, a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners, a New York-based healthcare private equity firm. Wechs
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres
- Keloid Breakthrough: Mount Sinai Researchers Show Keloid Shrinkage with Dupilumabhttps://practicaldermatology.com/news/keloid-breakthrough-mount-sinai-researchers-show-keloid-shrinkage-with-dupilumab/2460223/Keloid lesions exhibit increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy, Mount Sinai researchers report. Researchers, led by Emma Guttman-Yassky, MD, PhD, Vice Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York,
- Citing Underperformance, Hologic Sells Cynosure Medical Aesthetics Business for $205Mhttps://practicaldermatology.com/news/hologic-to-sell-cynosure-medical-aesthetics-business-for-205m/2460221/Hologic is selling Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. This is a tenth of the $1.6B that Hologic, a women's&n
- Kylie Jenner Sells $600 Million Majority Stake in Beauty Business to Cotyhttps://practicaldermatology.com/news/kylie-jenner-sells-600-million-majority-stake-in-beauty-business-to-coty/2460220/Kylie Jenner sold a majority stake in Kylie Cosmetics and Kylie Skin to Coty Inc. Under the terms of the agreement, Coty will acquire a 51 percent ownership in the partnership for $600M. The acquisition is expected to close in the third quarter of fiscal year 2020. Coty's family of
- Melanoma Rates Drop Sharply Among Teens, Young Adultshttps://practicaldermatology.com/news/melanoma-rates-drop-sharply-among-teens-young-adults/2460217/Cases of melanoma among U.S. adolescents and young adults declined markedly from 2006 to 2015 - even as the skin cancer's incidence continued to increase among older adults and the general population during the span, new research in JAMA Dermatology shows. The finding,
- Allergan Pays Exicure $25M upfront in Collaboration Deal to Develop Hair Loss Treatmenthttps://practicaldermatology.com/news/allergan-pays-exicure-25m-upfront-in-collaboration-deal-to-develop-hair-loss-treatment/2460216/Allergan Pharmaceuticals International Limited has entered into a global collaboration agreement with Exicure to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Allergan will receive exclusive access and options to licen
- Live Zoster Vaccine Safe and Effective for Patients on TNF Blockershttps://practicaldermatology.com/news/live-zoster-vaccine-safe-and-effective-for-patients-on-tnf-blockers/2460213/The live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications, according to
- Researchers Elucidate Why Some Beta Blockers May Trigger or Exacerbate Psoriasishttps://practicaldermatology.com/news/researchers-elucidate-why-some-beta-blockers-may-trigger-or-exacerbate-psoriasis/2460211/Beta-blockers can trigger or exacerbate psoriasis, and now scientists at the University of Bonn and Freie Universität Berlin may know why. It appears that beta-blockers can interfere with the breakdown of defective cell components. In return, the cells release messengers that trigger immune-